- LP-184 demonstrated anti-tumor activity in brain metastases
cell models from lung, skin, and breast cancers.
- Brain metastases in the U.S. can occur in 10-30% of all cancer
cases and are diagnosed in over 100,000 patients each year.
- Data supports continued development of LP-184 in CNS cancer
indications where there is an urgent and unmet clinical need.
DALLAS, March 14, 2022 /PRNewswire/ -- Lantern Pharma
Inc. (NASDAQ: LTRN), a clinical stage
biopharmaceutical company using its proprietary
RADR® artificial intelligence ("A.I.") and machine
learning (ML) platform to transform the cost, pace, and timeline of
oncology drug discovery and development, today announced that it
will present positive preclinical data on the in vitro efficacy of
its drug candidate LP-184 in brain metastases (mets) at the
American Association of Cancer Research (AACR) annual meeting,
April 8-13th, 2022, held
in New Orleans, Louisiana.
![Lantern Pharma (LTRN) Logo (PRNewsfoto/Lantern Pharma) Lantern Pharma (LTRN) Logo (PRNewsfoto/Lantern Pharma)](https://mma.prnewswire.com/media/1216507/Lantern_Pharma_Logo.jpg)
LP-184 is a small molecule drug candidate and next generation
acylfulvene that preferentially damages DNA in cancer cells that
overexpress certain biomarkers and is therefore lethal in tumors
that harbor mutations or deficiencies in DNA repair pathways.
LP-184 has already been demonstrated preclinically to have potent
efficacy in several targeted central nervous system (CNS) cancer
indications, including glioblastoma multiforme (GBM) and atypical
teratoid rhomboid tumors (ATRT). The development promise for LP-184
in these indications is strengthened by LP-184's favorable blood
brain barrier (BBB) permeability. LP-184 has also demonstrated
potent tumor cell killing capabilities in vitro and in animal
xenografts of tumors such as lung, breast, melanoma and colon, many
of which frequently metastasize to the brain. The tumor specificity
of LP-184 is driven by expression levels of PTGR1, and Lantern's
RADR® analysis indicates that such expression
levels are retained in brain mets of these primary tumors.
The virtual poster will be presented by Lantern Pharma in
collaboration with Johns Hopkins School of
Medicine and the Kennedy Krieger Institute and will describe
positive preclinical data demonstrating the effectiveness of LP-184
treatment in brain mets cell models derived from patient lung,
skin, and breast cancers. The poster will also show that in an in
vitro model of brain mets from lung cancer, LP-184 treatment was
found to be 6 times more potent than EGFR tyrosine kinase
inhibitors (a widely used type of therapy).
Brain mets are more common than primary brain tumors (cancer
that starts in the brain), and studies suggest that brain mets
occur in about 10%-30% of patients with cancer. In the U.S., brain
mets (from all cancers combined) are estimated to account for over
100,000 diagnoses annually and generally have a very poor prognosis
even after radiation therapy. There is an urgent and unmet clinical
need for novel therapies for brain mets due to a current lack of
novel agents that can cross the blood brain barrier. LP-184's
favorable BBB permeability paired with its observed preclinical
efficacy in certain CNS cancers, underscore its potential to become
a vital treatment option for patients relapsed from current
standard of care treatment or for use in combination with other
agents.
LP-184 was recently granted Orphan Drug Designation by the U.S.
Food and Drug Administration for the treatment of malignant
gliomas, pancreatic cancer, and ATRT, and was also granted a Rare
Pediatric Disease Designation for ATRT. These designations and
continued positive preclinical data will help to accelerate LP-184
towards IND submission and multiple Phase 1 clinical trials in
2022.
Details of the virtual poster presentation are listed below or
can be found on the AACR website:
Title: LP-184, a tumor site activated small molecule
synthetic lethal therapeutic, is effective in central nervous
system cancers
Permanent Abstract number: 5442
Date and Time: April 8, 2022,
12:00pm-1:00pm CST
Session Category: Experimental and Molecular
Therapeutics
Session Title: Small Molecule Therapeutic Agents
Presenter: Aditya Kulkarni, Ph.D., Lantern Pharma
About Lantern Pharma
Lantern Pharma (NASDAQ: LTRN) is
a clinical-stage oncology-focused biopharmaceutical company
leveraging its proprietary RADR® A.I. and machine
learning platform to discover biomarker signatures that identify
patients most likely to respond to its pipeline of
genomically-targeted therapeutics. Lantern is currently developing
four drug candidates and an ADC program across eight disclosed
tumor targets, including two phase 2 programs. By targeting drugs
to patients whose genomic profile identifies them as having the
highest probability of benefiting from the drug, Lantern's approach
represents the potential to deliver best-in-class outcomes.
Contact
Nicole Leber
Investor Relations Associate
ir@lanternpharma.com
Please find more information at:
Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/
Twitter: @lanternpharma
Forward-looking Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements include, among other things, statements relating to:
future events or our future financial performance; the potential
advantages of our RADR® platform in identifying drug
candidates and patient populations that are likely to respond to a
drug candidate; our strategic plans to advance the development of
our drug candidates and antibody drug conjugate (ADC) development
program; estimates regarding the development timing for our drug
candidates and ADC development program; our research and
development efforts of our internal drug discovery programs and the
utilization of our RADR® platform to streamline the drug
development process; our intention to leverage artificial
intelligence, machine learning and genomic data to streamline and
transform the pace, risk and cost of oncology drug discovery and
development and to identify patient populations that would likely
respond to a drug candidate; estimates regarding potential markets
and potential market sizes; sales estimates for our drug candidates
and our plans to discover and develop drug candidates and to
maximize their commercial potential by advancing such drug
candidates ourselves or in collaboration with others. Any
statements that are not statements of historical fact (including,
without limitation, statements that use words such as "anticipate,"
"believe," "contemplate," "could," "estimate," "expect," "intend,"
"seek," "may," "might," "plan," "potential," "predict," "project,"
"target," "objective," "aim," "upcoming," "should," "will,"
"would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that our research and the research of our
collaborators may not be successful, (iii) the risk that none of
our product candidates has received FDA marketing approval, and we
may not be able to successfully initiate, conduct, or conclude
clinical testing for or obtain marketing approval for our product
candidates, (iv) the risk that no drug product based on our
proprietary RADR® A.I. platform has received FDA
marketing approval or otherwise been incorporated into a commercial
product, and (v) those other factors set forth in the Risk Factors
section in our Annual Report on Form 10-K for the year ended
December 31, 2021, filed with the
Securities and Exchange Commission on March
10, 2022. You may access our Annual Report on Form 10-K for
the year ended December 31, 2021
under the investor SEC filings tab of our website at
www.lanternpharma.com or on the SEC's website at www.sec.gov. Given
these risks and uncertainties, we can give no assurances that our
forward-looking statements will prove to be accurate, or that any
other results or events projected or contemplated by our
forward-looking statements will in fact occur, and we caution
investors not to place undue reliance on these statements. All
forward-looking statements in this press release represent our
judgment as of the date hereof, and, except as otherwise required
by law, we disclaim any obligation to update any forward-looking
statements to conform the statement to actual results or changes in
our expectations.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lantern-pharma-to-present-positive-preclinical-data-on-the-effectiveness-of-lp-184-in-brain-metastases-at-the-american-association-of-cancer-research-aacr-annual-meeting-301501522.html
SOURCE Lantern Pharma